Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.
Also called NCT01356849
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 149 participants
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Registry
-
NCT01356849
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Puerto Rico, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01356849. Randomized; quadruple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2012-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
- Acronym
- RADAR
- Condition
- Chronic Kidney Disease
- Condition
- Diabetic Nephropathy
- Intervention (Drug)
- Atrasentan
- Intervention (Drug)
- Placebo
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
Record details
- Record id
cardio:ct-nct01356849- Content hash
f45da3301c5611ef0f98b3276f15288aafe7337127a689be08e657847d248eba